 BeiGene Ltd NASDAQ: BGNE announced positive topline results from an interim analysis of the Phase 3 SEQUOIA trial comparing Brukinsa zanubrutinib to bendamustine and rituximab BR. The trial included patients with treatment-naïve TN chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL whose tumor did not exhibit the deletion of chromosome 17p13.1 del17p. 